Aristolactams AII (30), BII (31), and velutinam (32) were evaluated for their ability to inhibit DYRK1A and CDK1/cyclin B kinases, that are related with neurodegenerative disorders, like Alzheimer's disease. Here, CDK1 is linked to early-onset autosomal dominant Alzheimer disease.